New drug cocktail shows early promise for Hard-to-Treat myeloma
NCT ID NCT03702725
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a combination of three drugs—ibrutinib, lenalidomide, and dexamethasone—in 14 people with multiple myeloma that had come back or stopped responding to prior treatments. The main goal was to find safe doses and watch for side effects. Results help guide future research on whether this combo can better control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ibrutinib (Imbruvica) combined with lenalidomide (Revlimid) and dexamethasone (Decadron)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with multiple myeloma that has returned or stopped responding to therapy.
What could go wrong
This is a very early phase 1 trial with only 14 participants, so safety and dosing are still being figured out. The combination may cause serious side effects like low blood counts or blood clots, and it is too soon to know if it truly helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
The Ohio State University Wexner Medical Center/James Cancer Hospital
Columbus, Ohio, 43210, United States
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States